Revenue Recognition
 3 Months Ended
Oct. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
The following table gives information as to the net sales disaggregated by geography and product line:
 Three Months Ended October 31,
Net sales by geography20202019
United States$215,087 $190,084 
Europe/Africa/Middle East47,785 41,018 
Asia/Pacific19,931 17,065 
Canada11,499 7,833 
Latin America/South America2,727 1,246 
Total$297,029 $257,246 
Net sales by product line
Capital equipment$48,640 $58,748 
Consumables167,350 153,279 
Product service33,459 31,568 
Instrument45,430 13,520 
All other(1)
2,150 131 
Total$297,029 $257,246 
_______________________________________________
(1)Primarily includes software licensing revenues.

Remaining Performance Obligations

At October 31, 2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $81,556, primarily within the Medical segment. We expect to recognize revenue on approximately 70% of these remaining performance obligations over the remainder of fiscal 2021 and fiscal 2022. These performance obligations primarily reflect the future product service revenues for multi-period service arrangements.
Contract Liabilities

A summary of contract liabilities activity follows:
Three Months Ended October 31,
20202019
Beginning balance$26,520 $28,235 
Revenue deferred in current year18,300 2,007 
Deferred revenue recognized(15,590)(2,982)
Foreign currency translation33 104 
Ending balance29,263 27,364 
Contract liabilities included in Other long-term liabilities(809)(384)
Deferred revenue$28,454 $26,980 
Our contract liabilities arise primarily in the Medical and Life Sciences segments when payment is received upfront for various multi-period extended service arrangements. We expect to recognize substantially all of this revenue over the next twelve months.